View Post

Lilly reports positive PRO from high-risk early breast cancer trial

In Clinical Studies News by Barbara Jacoby

From: clinicaltrialsarena.com Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC).  Eli Lilly has reported positive patient-reported outcomes (PRO) from a late-stage trial testing the efficacy of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC). The move comes after a primary outcome analysis …

View Post

Lilly’s Verzenio scores a win in early-stage breast cancer

In Clinical Studies News by Barbara Jacoby

Positive data was presented at 2020 ESMO virtual congress In the monarchE trial, patients with hormone receptor positive (HR+), HER2-negative high-risk early breast cancer were given Verzenio (abemaciclib) in combination with endocrine therapy. In addition to cutting the risk of cancer recurrence by 25%, 7.8% of the Verzenio treatment group had a relapse compared to 11.3% of patient in the …

View Post

It’s Right to Unite: Why Cross-functional Collaboration will Drive the Future of Engagement

In In The News by Barbara Jacoby

From: eloqua.eyeforpharma.com This article has been written in the build-up to the eyeforpharma Marketing Disruption Summit USA (Philadelphia, October 2-3, 2019) where leaders from the Marketing, Digital and Commercial space will join to learn how to deliver a blueprint to revitalize customer relationships. Much has been written about the value of patient- and customer-centricity in pharma but achieving this in …

View Post

Lilly’s CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

In Clinical Studies News by Barbara Jacoby

From: prnewswire.com Global, randomized, placebo-controlled study confirms CYRAMZA, in combination with erlotinib, significantly delayed disease progression in previously untreated patients with metastatic non-small cell lung cancer whose tumors have activating EGFR mutations Global regulatory submissions to be initiated this year  Second positive Phase 3 study of CYRAMZA in metastatic non-small cell lung cancer Eli Lilly and Company (NYSE: LLY) today …

View Post

Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis

In Clinical Studies News by Barbara Jacoby

Source: PRNewswire From: biospace.com Subgroup analyses demonstrate consistent benefit in subgroups of patients with a more concerning prognosis such as those with liver metastases, PR-negative disease, high tumor grade, or shorter treatment-free interval Eli Lilly and Company (NYSE: LLY) today announced npj Breast Cancer published results from exploratory subgroup analyses of the MONARCH 2 and MONARCH 3 trials reinforcing the clinical …

View Post

Eli Lilly wins U.S. approval for breast cancer drug

In In The News by Barbara Jacoby

By: Bill Berkrot From: reuters.com The U.S. Food and Drug Administration said on Thursday it approved an Eli Lilly and Co drug to treat advanced breast cancer that has progressed following prior treatment. The drug, abemaciclib, which will be sold under the brand name Verzenio, will carry a list price before any discounts or rebates of about $10,948 per month, …

Combo Drug Therapy May Work Best to Strengthen Bones: Study

In In The News by Barbara Jacoby

TUESDAY May 14, 2013 — A new combination drug therapy for osteoporosis appears to increase bone density more effectively thanany treatment now on the market, according to the results of a small clinical trial. Researchers found that postmenopausal women experienced significant amounts of bone growth by taking a bone-building drug called teriparatide with denosumab, a targeted therapy drug used to …